King Pharmaceuticals - Top 10 Layoffs of 2009
Company: King Pharmaceuticals
Layoffs: 770
Scoop: In early February, Bristol, Tennessee-based King Pharmaceuticals announced its intention to eliminate roughly 770 employees--a workforce reduction of approximately 22 percent. The company decided to eliminate 520 positions--380 field sales jobs and 140 corporate/admin jobs--following a January ruling in the U.S. District Court for the Eastern District of New York that two patents covering the muscle relaxant Skelaxin are invalid. If King's appeal is ultimately rejected, Skelaxin will face stiff generic competition sooner than it would have otherwise.
The other 250 cuts were designed to trim overlap created when King bought Alpharma. After the dust settles, King will be left with a field sales force of about 720.
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: